JP6205175B2 - 精神・神経疾患バイオマーカー - Google Patents

精神・神経疾患バイオマーカー Download PDF

Info

Publication number
JP6205175B2
JP6205175B2 JP2013104124A JP2013104124A JP6205175B2 JP 6205175 B2 JP6205175 B2 JP 6205175B2 JP 2013104124 A JP2013104124 A JP 2013104124A JP 2013104124 A JP2013104124 A JP 2013104124A JP 6205175 B2 JP6205175 B2 JP 6205175B2
Authority
JP
Japan
Prior art keywords
psychiatric
chain
immunoglobulin
neurological disorder
free
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2013104124A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014224759A (ja
JP2014224759A5 (https=
Inventor
新 大西
新 大西
敬史 南本
敬史 南本
哲也 須原
哲也 須原
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
RESVO INC.
Original Assignee
RESVO INC.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by RESVO INC. filed Critical RESVO INC.
Priority to JP2013104124A priority Critical patent/JP6205175B2/ja
Priority to EP14797879.5A priority patent/EP3002588B1/en
Priority to PCT/JP2014/057227 priority patent/WO2014185145A1/ja
Priority to US14/891,301 priority patent/US10041954B2/en
Publication of JP2014224759A publication Critical patent/JP2014224759A/ja
Publication of JP2014224759A5 publication Critical patent/JP2014224759A5/ja
Priority to US15/645,907 priority patent/US20180120328A1/en
Application granted granted Critical
Publication of JP6205175B2 publication Critical patent/JP6205175B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/6857—Antibody fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/525—Tumor necrosis factor [TNF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5412—IL-6
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/545—IL-1
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry
    • G01N2800/301—Anxiety or phobic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry
    • G01N2800/302—Schizophrenia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry
    • G01N2800/304—Mood disorders, e.g. bipolar, depression

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2013104124A 2013-05-16 2013-05-16 精神・神経疾患バイオマーカー Active JP6205175B2 (ja)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2013104124A JP6205175B2 (ja) 2013-05-16 2013-05-16 精神・神経疾患バイオマーカー
EP14797879.5A EP3002588B1 (en) 2013-05-16 2014-03-18 Use of a biomarker for diagnosing schizophrenia
PCT/JP2014/057227 WO2014185145A1 (ja) 2013-05-16 2014-03-18 精神・神経疾患バイオマーカー
US14/891,301 US10041954B2 (en) 2013-05-16 2014-03-18 Biomarker for psychiatric and neurological disorders
US15/645,907 US20180120328A1 (en) 2013-05-16 2017-07-10 Biomarker for psychiatric and neurological disorders

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2013104124A JP6205175B2 (ja) 2013-05-16 2013-05-16 精神・神経疾患バイオマーカー

Publications (3)

Publication Number Publication Date
JP2014224759A JP2014224759A (ja) 2014-12-04
JP2014224759A5 JP2014224759A5 (https=) 2016-07-28
JP6205175B2 true JP6205175B2 (ja) 2017-10-04

Family

ID=51898130

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013104124A Active JP6205175B2 (ja) 2013-05-16 2013-05-16 精神・神経疾患バイオマーカー

Country Status (4)

Country Link
US (2) US10041954B2 (https=)
EP (1) EP3002588B1 (https=)
JP (1) JP6205175B2 (https=)
WO (1) WO2014185145A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6205175B2 (ja) 2013-05-16 2017-10-04 株式会社Ｒｅｓｖｏ 精神・神経疾患バイオマーカー
JP7301327B2 (ja) * 2017-11-24 2023-07-03 学校法人 京都産業大学 マウスのうつ及び／又は不安症バイオマーカー
JP6737995B2 (ja) * 2018-11-29 2020-08-12 株式会社Ｒｅｓｖｏ 精神疾患発症危険状態の診断用バイオマーカー
GB202000634D0 (en) * 2020-01-15 2020-02-26 Nat Institute Of Mental Health Diagnostic method
JP6817666B2 (ja) * 2020-06-24 2021-01-20 株式会社Ｒｅｓｖｏ 精神疾患発症危険状態の診断用バイオマーカー

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0523949B1 (en) * 1991-07-15 2003-06-25 The Wellcome Foundation Limited Production of antibodies
US20060191026A1 (en) 2005-02-18 2006-08-24 Origen Therapeutics, Inc. Tissue specific expression of antibodies in chickens
EP2322200A3 (en) 2002-10-29 2011-07-27 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
WO2007094472A1 (ja) * 2006-02-17 2007-08-23 Atsuo Sekiyama 生体負荷の指標剤および生体負荷の測定方法
GB0724735D0 (en) 2007-12-19 2008-01-30 Psynova Neurotech Ltd Methods and biomarkers for diagnosing and monitoring psychotic disorders
US20120135542A1 (en) 2009-06-05 2012-05-31 Mayo Foundation For Medical Education And Research Methods and materials for diagnosing light chain amyloidosis
GB0915736D0 (en) * 2009-09-09 2009-10-07 Cambridge Entpr Ltd Biomarkers
GB201008340D0 (en) * 2010-05-19 2010-07-07 Cambridge Entpr Ltd Biomarkers
JP5641471B2 (ja) 2010-06-29 2014-12-17 国立大学法人名古屋大学 統合失調症マーカー及びその利用
JP2014500503A (ja) * 2010-12-06 2014-01-09 リッジ ダイアグノスティックス，インコーポレイテッド 精神神経疾患の処置をモニタリングするためのバイオマーカー
US20120238837A1 (en) * 2011-03-16 2012-09-20 Searete Llc, A Limited Liability Corporation Of The State Of Delaware System, devices, and methods for real-time monitoring of cerebrospinal fluid for markers of progressive conditions
JP6205175B2 (ja) 2013-05-16 2017-10-04 株式会社Ｒｅｓｖｏ 精神・神経疾患バイオマーカー

Also Published As

Publication number Publication date
EP3002588A4 (en) 2017-08-23
JP2014224759A (ja) 2014-12-04
US10041954B2 (en) 2018-08-07
EP3002588A1 (en) 2016-04-06
US20160131663A1 (en) 2016-05-12
US20180120328A1 (en) 2018-05-03
EP3002588B1 (en) 2022-01-12
WO2014185145A1 (ja) 2014-11-20

Similar Documents

Publication Publication Date Title
Fazio et al. Antiacquaporin 4 antibodies detection by different techniques in neuromyelitis optica patients
KR101531949B1 (ko) 아밀로이드 베타 펩티드의 개선된 검출 방법 및 시약
JP5998318B2 (ja) 新規血管炎の検査方法および検査用試薬
US20180120328A1 (en) Biomarker for psychiatric and neurological disorders
US7682795B2 (en) Method of diagnosing Alzheimer's Disease
WO2012107450A1 (en) Diagnostic method for urinary tract infection
ES2642723A1 (es) Uso de los niveles de anticuerpos anti-CD26 como biomarcadores de enfermedades autoinmunes y/o inflamatorias.
EA034364B1 (ru) Иммуноанализ для обнаружения хромогранина а
US20170067910A1 (en) Detection of Platelet-Derived Shed CD31
JP2016040540A (ja) ドレブリンａ及びドレブリンｅの特異的定量法
KR101486548B1 (ko) 나이관련 황반변성 진단용 마커 및 이를 이용한 나이 관련 황반 변성 진단 방법
IL263517B2 (en) Gamma-glutamyl-l-epsilon-lysine-specific monoclonal antibody for monitoring apoptosis
JP2009294096A (ja) 高安動脈炎の診断方法およびそれに用いられる診断キット
RU2661022C2 (ru) Изоформы тропомиозина, связанные с болезнью альцгеймера и умеренными когнитивными нарушениями
JP5961608B2 (ja) ＥｐｈＡ４細胞外ドメインの測定による認知機能障害を伴う神経系疾患の検出方法
JP6737995B2 (ja) 精神疾患発症危険状態の診断用バイオマーカー
JP6817666B2 (ja) 精神疾患発症危険状態の診断用バイオマーカー
JP2017106884A (ja) 甲状腺刺激ホルモンレセプター抗体アイソタイプ測定を用いたバセドウ病の病態診断キット及びバセドウ病の病態の診断方法
WO2016186173A1 (ja) 劇症肝不全の診断方法、及び予防又は治療剤
JP2013101047A (ja) １４−３−３蛋白γアイソフォーム特異的ＥＬＩＳＡ

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20150917

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20150917

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160513

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160513

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20160516

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170418

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170515

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170601

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170601

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170815

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170904

R150 Certificate of patent or registration of utility model

Ref document number: 6205175

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350